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Background: The correlations of genotypic and phenotypic tests with treatment, clinical history and the
significance of mutations in viruses of HIV-infected patients are used to establish resistance mutations to protease
inhibitors (PIs). Emerging mutations in human immunodeficiency virus type 1 (HIV-1) protease confer resistance to
PIs by inducing structural changes at the ligand interaction site. The aim of this study was to establish an in silico
structural relationship between natural HIV-1 polymorphisms and unusual HIV-1 mutations that confer resistance to
PIs.
Results: Protease sequences isolated from 151 Mexican HIV-1 patients that were naïve to, or subjected to
antiretroviral therapy, were examined. We identified 41 unrelated resistance mutations with a prevalence greater
than 1%. Among these mutations, nine exhibited positive selection, three were natural polymorphisms (L63S/V/H) in
a codon associated with drug resistance, and six were unusual mutations (L5F, D29V, L63R/G, P79L and T91V). The
D29V mutation, with a prevalence of 1.32% in the studied population, was only found in patients treated with
antiretroviral drugs. Using in silico modelling, we observed that D29V formed unstable protease complexes when
were docked with lopinavir, saquinavir, darunavir, tipranavir, indinavir and atazanavir.
Conclusions: The structural correlation of natural polymorphisms and unusual mutations with drug resistance is
useful for the identification of HIV-1 variants with potential resistance to PIs. The D29V mutation likely confers a
selection advantage in viruses; however, in silico, presence of this mutation results in unstable enzyme/PI complexes,
that possibly induce resistance to PIs.
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Diversity of viral populations is a result of sophisticated
recombination, replication and/or selection events that
induce drug-resistant human immunodeficiency virus
type 1 (HIV-1) variants. The lack of reverse transcription
corrections, transitional printing and transversion muta-
tions, along with viral recombination, has resulted in the* Correspondence: eduardo.vazquez@imss.gob.mx
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distribution, and reproduction in any mediumemergence of HIV-1 variants with high resistance to
pharmacological stressors [1,2]. These variants form
populations that evade antiretroviral agents, due to
emerging phenotypic changes within and around the ac-
tive enzyme site [3]. These mutations, which give rise to
drug resistance, result in reduced efficacy of highly ac-
tive antiretroviral therapy (HAART) [4]. Correlations be-
tween genotypic and phenotypic tests with treatment,
clinical history, and significance of mutations identified
in HIV-1 of infected patients are used to determine the
presence of mutations that confer resistance to protease
inhibitors (PIs) [1].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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finity between proteins and their inhibitors, and has been
recognized as a property of drug resistant HIV-1 proteins
[5,6]. Protein folding simulation models can create Local
Elementary Structures (LES). These secondary structures
are stabilized by amino acids that interact with the polypep-
tide chain [7]. Using the Gromacs software (version 3.0),
LES were found to form in protease (PR) regions 23–33,
74–78, and 83–92, and also docked in a folding nucleus [8].
Other studies have shown that mutations further from the
active site can alter the flexibility of HIV-1 PR, inducing
structural changes that affect the efficacy of most PIs cur-
rently used [9]. Theoretical studies, either alone or in com-
bination with experimental methods, have pointed to an
increase in the flexibility of mutant enzymes at various sites,
including the active site, as a resistance mechanism that
causes a decrease in the affinity of PIs [10]. Part of the
cause of such flexibility could be the unusual mutations
that generally emerge only after "major" and "minor" resist-
ance mutations have been introduced [11]. Other muta-
tions that can affect the interaction between PR and PIs are
natural polymorphisms and unusual mutations in positions
that confer drug resistance. Although the main mutations
associated with drug resistance have been characterized
[12,13], little is known about the influence of natural poly-
morphisms and unusual mutations with respect to the de-
velopment of drug resistance. The aim of this study was to
describe an in silico experiment that showed structural cor-
relations between natural HIV-1 polymorphisms and un-
usual HIV-1mutations in the PR region of HIV-1 pol with
potential PIs resistance.Methods
Sequence data
We analysed 151 HIV-1 sequences from Mexican pa-
tients who had been tested for resistance to antiretro-
viral drugs between 2005 and 2011 in the Laboratory of
Immunodeficiencies and Human Retroviruses, Western
Biomedical Research Center, Mexican Institute of Social
Security. Sequences were obtained from 22 naïve, and
129 treated patients that were not responsive to drugs.
Sequences were registered in the GenBank database
[14], with the following accession numbers: [EU045452–
EU045489; GU382757–GU382851; GU437199–GU4372
00; and KC416212–KC416227]. All sequences were ana-
lysed for the presence or absence of highly mutated se-
quences using HYPERMUT software (version 2.0) [15].
For a reference sequence, we used the subtype B consen-
sus sequence, which was derived from an alignment of
subtype B sequences maintained at the Los Alamos HIV
Sequence Database (LANL), and available from the
HIV Drug Resistance Database (HIVDB), Stanford Uni-
versity [16].Phylogenetic analysis
Nucleotide homology analysis for HIV-1 sequences was
conducted using the NCBI Genotyping Tool program
[17]. Subtype determinations were further confirmed by
phylogenetic analysis performed with the Molecular Evo-
lution Genetics Analysis (MEGA) software package (ver-
sion 5.0) [18], which includes the recommended
reference sequence sets, available from the Los Alamos
HIV Sequence Database [19]. Prior to all phylogenetic
analyses, HIV-1 pol sequences were aligned using Clustal
X (European Bioinformatics Institute, EMBL) [20]. Se-
quences with 100% homology were excluded from the
analysis. The nucleotide distance matrix was generated
using the Kimura two-parameter Neighbour-joining
method [21]. The statistical robustness of the generated
trees was verified by bootstrap analysis of 1000
replicates.
Detection of multidrug resistance phenotypes in HIV-1
protease
The genetic changes associated with drug resistance in viral
sequences were established according to HIVdb algorithm
version 6.0.9 (http://hivdb.stanford.edu) [22]. The interpret-
ation of drug resistance was performed at various levels of
susceptibility for the following USA Food and Drug
Administration (FDA)-approved PIs: atazanavir (ATV); dar-
unavir (DRV); amprenavir (APV); indinavir (IDV); lopinavir
(LPV); saquinavir (SQV); tipranavir (TPV); nelfinavir
(NFV);and ritonavir (RTV). The resistance mutations were
classified as major or minor according to HIVdb criteria, or
as natural polymorphisms or unusual mutations if they
were not associated with resistance [16]. The prevalence (p)
for each mutation in the protease region of pol was quanti-
tatively determined as the frequency of the mutation (M)
among total sequences evaluated for each position (N), p =
M/N, using Microsoft Excel 2010. The genetic variation
was calculated as the total number of mutations at a nu-
cleotide position divided by the number of evaluated se-
quences. The Phenotypic Variation (PV) was defined as the
percentage (%) of amino acid substitutions for each position
relative to the consensus sequence. For each region, the PV
was classified as follows: conserved, <1%; semi-conserved, 1
to <5%; variable, 5 to <10%; and highly variable, ≥10%.
Values found below the 15th percentile and above the 75th
percentile were not considered. Phenotypic mutations with
a prevalence of ≥1.0% among 151 amino acid sequences
were compared for each PI against the IAS–USA drug re-
sistance mutations list [12]. The structural conservation of
PR was defined in a complementary way to that of PV.
Analysis of selective pressure
The selective pressure and reconstruction of the ances-
tral state for each PR codon was determined using a
maximum likelihood (ML) substitution model and the
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The synonymous site divergence (dS) and nonsynon-
ymous site divergence (dN) per branch was estimated
using the Muse–Gaut codon model [25]. The values of
the ML model were estimated from the topology of the
phylogenetic tree. The probability of rejecting the
hypothesis of neutral evolution was significant with
p ≤ 0.05. The standardized values of dN–dS were ob-
tained by the total number of substitutions in the tree
(calculated as substitutions expected by site). To distin-
guish between drug pressure and immune system pres-
sure, results were compared using the HIV positive
selection mutation database [26].
Molecular modelling
Once the natural polymorphisms and unusual mutation co-
dons with positive selection (dN/dS > 1) and prevalence
>1% were obtained, homology modelling was used to pre-
dict changes in the PR structure. Homology modelling of
natural polymorphisms and unusual mutations followed
these steps: (i) template selection; (ii) structural alignment;
(iii) model construction; and (iv) refinement [27]. To select
the template, HIV-1 protease X-ray crystal structure
FASTA sequences available from the Protein Data Bank
(PDB) [28] and the HIV-1 subtype B consensus sequence
available from the HIVdb were aligned using ClustalX [20].
The PR sequence exhibiting greatest identity with HIV-1
subtype B consensus (wild-type template) was chosen as
the template for modelling mutant proteases (PRs). The re-
sistant PRs used for reference were modelled with each
major PI resistance mutation. Every mutant protein was
modelled using a Swiss-Model workspace, which showed
the identity (%). The expected alignment value with the
template sequence (E) and the Qualitative Model Energy
Analysis (QMEAN4), which estimates the absolute quality
model, ranged from 0–1 [28,29].
Estimation of the free energy of binding
Using the Autodock/Vina application on a LINUX plat-
form, which had the PyMOL (version 1.4.1) molecular
graphics system installed, we estimated the free energy
of binding of the complex between mutant PR structures
and Pls [30]. Rectangular boxes were used to define the
binding sites and these were adjusted by providing spe-
cific coordinates of active PR sites before each docking.
Receptor and ligand representations in the Protein Data
Bank, Partial Charge & Atom Type formats (pdbqt) con-
taining atomic charges, atom type definitions and topo-
logical information, were produced using Autodock/Vina
[30]. To determine if the differences caused by natural poly-
morphisms and unusual mutations had any effect on the
free energy of binding of Pls, the free energy values ob-
tained for the resistant protease/ligand complexes were
compared. Natural polymorphisms or unusual mutationswith lower or equal affinity to PIs compared with reference
proteins containing drug resistance mutations indicate
positive resistance. Higher affinity was considered to favour
susceptibility of the HIV-1 variant to PIs. The coupled pro-
teases included the wild-type PR [PDB: 1GNO], PRs with
major drug-resistance mutations and PRs with natural poly-
morphisms or unusual mutations at codons having positive
selection.
Measurement of distances between protease residues
and PIs
To evaluate the natural polymorphism and unusual mu-
tation atoms that affect the affinity of PIs, we measured
the distances (Å) between the amino acid residue Cα-
atoms implicated in drug resistance, and the closest het-
eroatoms of the PIs. Complexes that showed signs of
free energy of binding were analysed, suggesting in-
creased drug resistance because of the presence of nat-
ural polymorphisms and unusual mutations. Distances
were compared with those obtained for the same pair of
atoms in the wild-type and resistant PR structures avail-
able from the PDB [28]. All interatomic distances were
measured with PyMOL (version 1.4.1) [31].
Results and discussion
Genetic relationships of HIV-1 variants isolated from
Mexican patients
Phylogenetic analysis of the 151 HIV-1 protease fragment
nucleotide sequences was conducted using a Neighbour-
joining tree. Phylogenetic relationships were grouped into
the internal nodes of the tree, using subtype B reference se-
quences [GenBank: U63632 and U21135]. The HIV-1 vari-
ants isolated from Mexican patients, and confirmed by
analysis with the NCBI Genotyping Tool, were subtype B.
This result is consistent with other molecular epidemiology
studies of Mexican HIV-1 patients, with or without anti-
retroviral intervention, where subtype B prevails [32,33].
Drug resistant phenotypes and genotypes of HIV-1
protease
Non-synonymous genetic changes largely contribute to
phenotypic changes [34]. Because of degeneracy in the gen-
etic code, transcription and translation errors during the
viral replication cycle, along with functional, structural,
pharmacological and immunological selection pressures,
there is no absolute mathematical relationship between gen-
etic and phenotypic variations [35]. Variations in the pri-
mary structure of the 151 PR sequences are presented in
Figure 1. Of the 36 codons associated with major or minor
resistance, 19 showed PV <5% (L11, L24, D30, V32, L33,
E34, K43, I47, G48, I50, F53, D60, G73, T74, L76, N83, I85,
N88 and L89). Among these codons, G48, I50 and F53 were
present in conserved regions, and L24, D30, L76 and N88 in
semi-conserved regions. Six codons (G16, K20, I54, Q58,
Figure 1 (See legend on next page.)
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Figure 1 Genetic and phenotypic representation of primary structure variation within the HIV-1 protease consensus. Codons 1–3 are
shown in grey and were not included in our analysis. Conserved regions are shown in yellow, semi-conserved regions in ochre, variable regions
in orange and highly variable regions in red. The major (dark green) and minor (light green) resistance mutations are indicated for each codon.
aGenetic variation = total number of mutations at the nucleotide position/number of sequences evaluated. bPhenotypic variation = total number
of mutations at the amino acid position/number of sequences evaluated.
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I54 and Q58 were located in conserved and semi-conserved
regions, respectively. The remaining 11 codons associ-
ated with drug resistance (L10, M36, M46, I62, L63,
I64, A71, V77, V82, L90 and I93) had variation >10%,
with L10 and I93 present in conserved regions, and
M46, V77 and L90 in semi-conserved regions. There
was also a variable PV of 5–10%, in the codons neigh-
bouring the drug resistance positions (T12, I15, L19,
G68, and K70), with codons E35, N37, R41, R57, and
I72 highly variable. Figure 2 illustrates the mutations
with prevalence ≥1% found in the protease region ofFigure 2 Prevalence of mutations within HIV-1 PR pol. Red bars repres
represent natural polymorphisms and unusual mutations not associated wiHIV-1 that were present in the 151 PR sequences ex-
amined. According to the IAS-USA, the mutations as-
sociated with drug resistance, with a p >10%, were
L10I, M36I, I62V, L63P, I64V, A71V/T, V77I, L90M,
and I93L [12,36,37].
Structural studies of PRs have reported a slight widen-
ing of the active site due to mutations associated with
drug resistance for the majority of PIs [9,10,38]. How-
ever for other inhibitors, such as IDV which is charac-
terized by three aromatic rings, structural changes are
caused by mutations at the active site and adjacent posi-
tions [39].ent mutations associated with drug resistance, and the green bars
th drug resistance.
Table 1 Polymorphisms or unusual mutations (p > 1%) weakly associated with PI resistance in HIV-1 protease from
treated and naïve individuals according to the HIVdb




Association with drug resistance Classification
W6R 2.34 8.20 C (0.98) Found in indinavir-resistant PR [44] UM
T12A/I 1.34/
1.34
9.40 V (8.04) T12A decreased in patients treated with PIs. [45] T12I appears in cell culture in the presence
of SQV [46]
NP/NP
I13V 17.33 18.33 V (8.04) Found in isolates from patients treated with NFV [47] NP
I15V 8.28 9.27 V (8.04) Associated with reduced virological response to RTV + SQV therapy [48] NP
E35D 18.21 18.54 HV(26.05) Associated with reduced in vivo virological responses to RTV/AMP [49] NP
N37D/E 9.27/
5.96
40.07 HV(26.05) N37D appears together with N37E in patient treated with LPV + RTV [50] NP/NP
R41K 19.00 19.00 SC(2.39) Associated with reduced in vivo virological responses to RTV + APV in PIs experienced
patients [49]
NP
R57K 17.88 18.38 * Relatively frequent in patients failing treatment with RTV + SQV [51] NP
L63A 3.48 84.77 HV(22.02) L63A frequent polymorphism but significantly associated with the antiretroviral treatment
[39,52]
NP
H69Y 3.15 7.62 V(7.56) Appears in viruses selected with LPV [53] NP
K70E 3.31 9.11 V(7.56) K70E appears in virus selected in cell culture with DRV [54] NP
I72R 1.32 24.50 HV(27.48) Associated with viral rebound during therapy with LPV + RTV [50] UM
p, prevalence; PV, phenotypic variation; C, conserved; SC, semi-conserved; V; variable; HV, highly variable; APV, amprenavir; ATV, atazanavir; DRV, darunavir; IDV,
indinavir; RTV, ritonavir; SQV, saquinavir; PIs, protease inhibitors; NP, natural polymorphisms; UM, unusual mutations.
*Values below the 15th percentile or above the 75th percentile were not considered.
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mutations in PRs without established drug resistance
Table 1 shows the natural polymorphisms or unusual mu-
tations with a p >1% that were found in the PR sequences
of HIV-1 isolated from the Mexican patients. These are
weakly associated with PI resistance, but are not included
in the IAS–USA guides or the HIVdb as accessory or
minor mutations [16,40,41]. Of the 14 mutations, only
L63A and H69Y were found in drug resistance positions,
and T12A/I, I15V, E35D, N37D/E, R57K, K70E and I72V
were contiguous to positions associated with resistance.
Overall, these mutations have little effect on drug suscep-
tibility; however, a phenotypic change in any of them
could have relevance to the affinity to one or more PIs
[6,42]. These mutations, in combination with resistance
mutations, might have an effect on the dynamics of the
evolution of cross-resistance [43].
The I13V (17.33%), E35D (18.21%), R41K (19%) and R57K
(17.88%) mutations had a p ≥ 10% and were located in poly-
morphic positions observed in non-B subtypes [35,55,56]. In
the HIVdb, W6R and I72R are unusual mutations with a
frequency <0.05% that only emerge after multiple major and
minor resistance mutations [57]. Table 2 shows 41 muta-
tions with a p >1% that have not been associated with resist-
ance, 25 are natural polymorphisms and the remaining 16
were unusual mutations. According to phenotypic conserva-
tion analysis, the L5F and Q7E mutations were within the
conserved regions, while D29V, P39S, K43R, Q61E, E65D,
C67F, P79L, T91V and Q92G/K were within semi-conserved
regions. The T12P/S, K14R, G17D/E, Q18H, L19I/V/T,G68E, H69Q and K70R/T/I mutations were within the vari-
able regions, and N37S/T/C/H/I, L63S/V/R/G/H, I72V/T/E/
M and I93F were in highly variable regions.
Among the codons presented in the Table 2, the muta-
tions in positions K43, L63, H69 and I93 were located in
sites associated with minor resistance, but the distance be-
tween its localization and the enzyme’s active site reduces
the possibility of the structure contributing to drug resist-
ance. All the described mutations could be due to random
transcriptional errors, or positive selection from drug and/
or immunological stressors [37,58]. Generally, natural
polymorphisms occur in remote regions away from the ac-
tive site, and form domains that define the shape of the
homodimer. However, unusual mutations are found in po-
sitions associated with drug resistance and possibly gener-
ate allosteric changes in the binding site that favour
enzymatic function, or decrease the affinity with certain
PIs [59]. Therefore, the study of such structural changes
produced by these emerging mutations may help in deter-
mining the new effects of PIs with different affinities.
Figure 3 shows PR tertiary structure positions that are:
not associated with PI resistance; weakly associated with
PI resistance; associated with PI resistance. We have also
presented the locations of natural polymorphisms and un-
usual mutations (Figure 3). The codons T12, N37, L63,
H69, K70 and I72 include mutations weakly associated
with PI resistance (T12A/I, N37D/E, L63A, H69Y, K70E,
and I72R), and mutations lacking evidence of PI resistance
(T12P/S, N37S/T/C/H/I, L63S/V/R/G/H, H69Q, K70R/T/
I, and I72V/T/E/M).
Table 2 Natural polymorphisms and unusual mutations of HIV-1 protease (p > 1%) without evidence of resistance to
PIs
Mutation p (%) PV (%) Region (PV) Classification
L5F 1.67 1.67 C (0.95) UM
Q7E 1.52 1.89 C (0.95) UM
T12P/S 4.03/1.34 9.40 V (8.04) NP/NP
K14R 9.60 11.26 V (9.97) NP
G17D/E 1.99/1.32 3.31 V (9.97) UM/UM
Q18H 1.32 3.64 V (9.97) NP
L19I/V/T 4.64/1.32/ 1.32 7.95 V (9.97) NP/NP/NP
D29V 1.32 2.65 SC(1.24) UM
N37S/T/C/H/I 14.4/2.81/1.99/ 1.66/1.32 40.07 HV(26.05) NP/NP/NP/NP/UM
P39S 2.98 4.97 SC(2.09) NP
K43R 3.64 3.97 SC(2.09) NP
Q61E 2.65 3.97 SC(4.47) NP
L63S/V/R/G/H 1.99/149/1.99/1.32/1.32 84.77 HV(22.02) NP/NP/UM/UM/NP
E65D 2.0 2.67 SC(2.0) NP
C67F 2.0 3.33 SC(2.0) NP
G68E 4.30 5.96 V(7.56) UM
H69Q 1.99 7.62 V(7.56) NP
K70R/T/I 1.99/1.32/1.16 9.11 V(7.56) NP/UM/NP
I72V/T/E/M 11.26/6.95/2.32/1.32 24.50 HV(27.48) NP/NP/NP/UM
P79L 1.32 2.48 SC(1.53) UM
T91V 3.33 3.33 SC(2.15) UM
Q92G/K 2.03/2.03 4.05 SC(2.15) UM/UM
I93F 1.35 47.97 HV(47.63) UM
p, prevalence; PV, phenotypic variation; C, Conserved; SC, semi-conserved; V, variable; HV, highly variable; NP, natural polymorphisms; UM, unusual mutations.
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active site of the protease, and therefore possibly con-
tribute to the generation of PI resistance. It is of interest
to evaluate these unusual mutations in silico, and estab-
lish their association with resistance to PIs.
Phenotypic conservation of HIV-1 protease
Figure 4 shows the conserved, semi-conserved, variable and
highly variable regions of PRs according to PV. Mutations
were clustered into 15 regions, for amino acids 4–99 of the
protease. For average PV calculation, when the asymmetry
in the distribution was greater than 1.4 between the 15th
and 75th percentiles, the residues were not considered. We
found three conserved, three variable, three highly variable
and six semi-conserved regions for each chain. The posi-
tions excluded from the PV calculated for each region were
W6, L10, I13, K14, G17, Q18, E35, G40, R41, M46, I54,
V56, R57, I63, V77, N83, L90, Q92, I93 and K97. The PV in
these codons had very different values from those presented
by the codons in their respective regions. According to our
model of protease conservation, the LES formed by frag-
ments 23–33 and 74–78 were in semi-conserved regions(E21–L34 and G73–P81, except for V77). The LES formed
by the 83–92 fragment involved two codons with variable
PV, I84 (6.29%) and L90 (12.33%), and two codons with
semi-conserved PV, T91 (3.33%) and Q92 (4.05%) [8,60].
Codon 90 contained a drug resistance mutation (L90M)
common for most PIs, with the exception of DRV and TPV,
while T91 and Q92 contained the T91V, Q92G, and Q92K
mutations, which are classified in the literature as unusual
mutations. The prevalence of the L90M, T91V, Q92G, and
Q92K mutations was 12.0, 3.33, 2.03 and 2.03%, respectively.
Although the effectiveness and specificity of PR proteolytic
activity is determined by its active site (amino acids 25–29),
these characteristics are influenced by mutations in neigh-
bouring structures, which mainly affect intramolecular inter-
actions with the active site [5,38,42,61]. Contiguous regions
and the active site have a semi-conserved state, with a PV of
1.2%. It has been shown that active sites with poor capacity
to carry out structural changes help adjust the specificity of
natural substrates without losing proteolytic effectiveness
[45]. A study that identified the minimal conserved structure
of HIV-1 PR, in the presence or absence of drug stress,
showed that most of the PV is a product of pharmacological















Codons without evidence Codons weakly associated Codons associated with 
Figure 3 Codons with natural polymorphisms and unusual mutations in the HIV-1 PR tertiary structure. Codons in the PR that were not
associated with PI resistance (cyan), weakly associated with PI resistance (yellow), and associated with PI resistance (red).
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a relatively high PV (for variable and highly variable regions)
courtesy of negative selection, and to a lesser extent through
resistance of HIV-1 to immune stress [63,64].
Selective pressure in the pr fragment of HIV-1 pol
Antiretroviral treatment can exert strong selective








1 to <5% Semi-conserved
5 to <10% Variable
10% Highly variable
Figure 4 Phenotypic conservation of HIV-1 PR isolated from Mexican
sequences. Regions are shown from red to yellow in proportion to their ph
unusual mutations at drug resistance codons are shown in the protease m
of the protease.transcriptase and integrase [62,65]. We have presented
the selection pressure results for 10 codons with natural
polymorphisms and unusual mutations (Table 3). Ac-
cording to these results, codons 5, 29, 63, 79, 91 and 93
represent positive pressure (dN–dS > 1) through the ML
substitution model using the HyPhy algorithm. When
these results are compared with the data available in the






C 1 T4 to P11 0.98 W6, L10
V 2 L12 to G20 8.04 I13, K14, G17, Q18
SC 3 E21 to L34 1.24
HV 4 E35 to N37 26.05 E35
SC 5 L38 to I47 2.39 G40, R41, M46
C 6 G48 to V56 0.37 I54, V56
SC 7 R57 to Q61 4.47 R57
HV 8 I62 to I64 22.02 I63
SC 9 E65 to C67 2.00
V 10 G68 to K70 7.56
HV 11 A71 to I72 27.48
SC 12 G73 to P81 1.53 V77
V 13 V82 to I84 8.45 N83
SC 14 I85 to Q92 1.83 L90, Q92
C 15 I93 to F99 0.44 I93, K97
Positions not 
considered
patients. A consensus sequence was obtained from 151 individual
enotypic variation (PV,%). Positions with natural polymorphisms and
odel. Mutations were clustered into 15 regions between codons 4–99
Table 3 Selection pressure for codons with unusual mutations and natural polymorphisms
Codon Triplet PV (%) dN-dS dN-dS (N) P value* Mutations
5 CTT 1.67 2.29 0.48 0.285 L5F
6 TGG 8.20 −5.97 −1.26 0.996 W6R
7 CAA 1.89 −15.57 −3.29 1.000 Q7E
29 GAT 2.65 20.20 4.26 0.003 D29V
63 CCC 84.77 2.01 0.42 0.196 L63A/R/S/V/G/H
70 AAA 9.11 −1.51 −0.32 0.964 K70I
79 CCT 2.48 4.44 0.94 0.190 P79L
91 ACT 3.33 5.01 1.12 0.086 T91V
92 CAG 4.05 −15.62 −3.46 0.990 Q92G;Q92K
93 ATT 47.97 28.64 6.34 1.000 I93F
*P < 0.05 was considered statistically significant for positive pressure.
PV, phenotypic variation; dN, number of non-synonymous substitutions per site (n/N); dS, number of synonymous substitutions per site (s/S); N, normalized;
P, probability.
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under immunological and/or pharmacological stressors
[26]. The difference in selection pressure for codons 5,
29, 79 and 91 could be due to variability in the antiretro-
viral regimen sequences administered to Mexican pa-
tients. In addition to positive selection, the aligned sites
often evolve at different rates because of other biological
factors that include site-specific mutation rates and
functional constraints of amino acid substitutions [66].
The codons that were not associated with resistance due
to pharmacological stress, and had PV ≥2% were D29
(2.65%) and P79 (2.48%). These were located near the ac-
tive site of the enzyme; T91 (3.33%) was also found to be
necessary for the establishment of the PR dimer. Codons
associated with resistance due to pharmacological stress
and PV ≥2% were I47 (2.65%), V82 (10.6%) and I84
(6.29%). Only one of these sequences belonged to a naïve
individual, with a mutation at V82; the remaining
sequences were from treated individuals (three were
treated with reverse transcriptase inhibitors only, the re-
mainder were given reverse transcriptase inhibitors and at
least one PI).
Structural prediction of mutant HIV-1 PRs
The molecular structure of all mutant HIV-1 PRs was
predicted by comparative homology modelling using the
wild-type HIV-1 PR as a template [PDB: 1GNO]. This
structure had higher sequence identity compared with
the HIV-1 subtype B consensus PR sequence available
from the HIVdb. Additional file 1: Table S1 shows the %
identity, the expected value of the alignment with the
template sequence (E), and the score for the absolute
quality of the models. We modelled the proteins with
unusual mutations (L5F, D29V, L63G, L63R, P79L and
T91V), natural polymorphisms (L63H andL63S), and
drug-resistant mutant PRs with single mutations or pat-
terns of mutations (D30N, V32I, M36I, M46I, I47V,G48V, I50V, I50L, I54M, Q58E, T74P, L76V, V82A, V82L,
N83D, N88S, I84V, and L90M).
The model’s accuracy was increased because of the iden-
tity between the mutant and template sequences; therefore,
we concluded that the model was suitable for all structures.
The low E values obtained from the modelled proteins indi-
cate template identification, and adequate target template
alignment [27]. The reliability of the predicted structures
with natural polymorphisms and unusual mutations in drug
resistance positions ranged 0.87–0.89, while positions for
major mutation proteins ranged 0.83–0.91. The lower
QMEAN4 values correlated with mutants containing pat-
terns of resistance, as a result of the reduced identity of
these proteins with respect to the template structure [67].
The QMEAN4 values were acceptable for all the modelled
structures. Figure 5 shows the overlapping structures of the
wild-type PR [PDB: 1GNO] and the D29V mutant, with
high similarity between both structures, as well as a differ-
ence in the location of the mutation site (position 29).
D29 plays a crucial role for the folding of retroviral PRs
[38,68]. Using crystallography, it has been shown that D29
forms hydrogen bonds with R87, which partially constitutes
the highly conserved triad, G86−R87−D88 [62]. The loss
of this specific interaction between α − helix 1 (residues 87–
91) and D29 destabilizes the dimer interface [69]. The PR
structures of related viruses such as HIV− 2, equine infec-
tious anaemia virus (EIAV), feline immunodeficiency virus
(FIV), rous sarcoma virus (RSV) and simian immunodefi-
ciency virus (SIV), also demonstrate a proximity between
side chains R87 and D29 [70].
The in silico modelling of mutant proteins generated
structures very similar to those obtained by X-ray crys-
tallography. The structures with natural polymorphisms,
unusual mutations in drug resistance positions, and drug
resistance mutations obtained by comparative homology
modelling, were appropriate for molecular docking with
their respective inhibitors.













Figure 5 Wild-type and D29V mutant protease structures. The structure of the wild-type HIV-1 protease (WT) was obtained by X-ray crystallography.
[PDB: 1GNO] (blue), and the mutant protease (green) can be clearly seen, with the red structures corresponding to the oxygen atoms of D29.
Mata-Munguía et al. BMC Bioinformatics 2014, 15:72 Page 10 of 17
http://www.biomedcentral.com/1471-2105/15/72Natural polymorphisms and unusual mutations in PRs
and their effects on the free energy of binding by PIs
We have presented the free energy of binding (kcal/mol), as
well as the average value of the five lowest energy conforma-
tions for the complexes formed by PRs and the main PIs
(Table 4). The wild-type PR had the lowest free energy of
binding for all PIs, except for IDV, compared with mutant
PRs containing major and multiple drug resistance muta-
tions. The magnitudes corresponding to the minor values of
the free energy of binding to the reference protein were:
wild-type protease-1GNO<major drug-resistant mutant pro-
teases <multiple drug-resistant mutant proteases. The PIs
had the greatest degree of affinity for PR 1GNO, consistent
with the wild-type PR, whereas reduced affinity for mutant
PRs was proportional to the number of mutations [46].
Among the PIs, IDV demonstrated a higher affinity for
mutant proteins than PR [PDB: 1GNO]. Additionally, a
study that correlated the in vivo genetic resistance of HIV-1
to IDV indicated that the development of resistance occurs
through the combined effects of several mutations, which
do not confer a measurable degree of resistance when they
occur on their own [39]. For the other PIs, significant viral
resistance has been shown to be a result of the appearance
of one or two substitutions in drug-resistance positions
[40,71].
The difference between affinities of complexes formed
by wild-type and drug-resistant PRs indicates some contri-
bution of phenotypic changes towards PI resistance
[72,73]. The complexes with the largest differences in-
volved ATV and DRV, both with a difference of −1.2 kcal/
mol. This indicates high susceptibility of both compoundsto drug resistance mutations. Lower differences were ob-
served (between −0.7 and −0.3 kcal/mol) for other com-
plexes, indicating these drug resistance mutations have a
minor or supplementary effect [72,73].
We obtained a positive value when we calculated the dif-
ference of the free energy of binding between the wild-
type-IDV complex and the drug-resistant mutant-IDV
complex. This is consistent with a high genetic barrier to
resistance for IDV, which has lower susceptibility to drug-
resistance mutations compared with other PIs [39]. When
comparing the free energy of binding between the com-
plexes with drug resistance mutations versus natural poly-
morphisms and unusual mutation complexes, resistance to
ATV, LPV, NFV, and TPV was always observed. The PRs
with L5F, D29V, L63G, L63H, L63R, L63S, and P79L muta-
tions had lower or equal free energy of binding to ATV,
LPV, NFV and TPV, than those with wild-type or drug-
resistant PRs.
The complex formed by the D29V mutant showed con-
siderable differences between the distance of the V29 and
D30 Cα -atoms and the heteroatoms closest to the PIs
(Table 4). This is probably because of the absence of the
Cβ carboxyl group in the valine compared with the wild-
type D29. The electrostatic interactions exercised by the
D29 carboxyl oxygens provide stronger affinity to PIs in
the active site, resulting in greater affinity compared with
the V29 mutant [5,74,75]. The absence of V29 carboxyl
oxygens decreases the level of interactions, thus decreas-
ing affinity. Such differences can be observed when meas-
uring the distance between the functional groups of the
wild-type, resistant and D29V mutant PRs docked to DRV
Table 4 Free energy of binding for protease-PI complexes obtained in silico
Inhibitor 1GNO-Ligand
kcal/mol
Mutant protease with major drug resistance mutation kcal/mol Multiple mutant
kcal/mol
Mutant protease with emergent mutations L5F/D29V/L63G/L63H/
L63R/L63S/P79L/T91V kcal/mol
Amprenavir -8,5(-8,4) -8,4(-7,9)/I50V -8,2(-8,12)/I84V -8,0(-7,66) -8,8(-8,38)/-8,7(-8,28) /-8,8(-8,44)/ -8,8(-8,3)/ -8,8(-8,48)/ -8,7(-8,28)/ -8,8
(-8,32)/-8,8(-8,48)
Atazanavir -8,3(-8,1) -7,3(-6,94)/I50L -8,5(-8,14)/I84V -8,2(-7,98)/N88S -7,1(-6,86) -7,9(-7,82)/ -8,2(-8,14)/ -8(-7,62)/-8,1(-7,96)/ -8,2(-8,04)/-8,2(-8,06)/-9(-8,8)/-
8,2(-8)
Darunavir -9,3(-8,96) -9(-8,54)/I47V -9,3(-8,86)/I50V -9,4(-8,84)/I54M -9,1(-8,86)/ I84V -8,1(-7,9) -9,4(-9)/ -8,8(-8,56)/-9,4(-8,9)/-9,4(-8,92)/ -9,4(-8,92)/-9,4(-8,88) /-9,4(-8,86)/-
9,4(-8,88)
Indinavir -10,4(-10,02) -10,8(-10,5)/M46I -10,8(10,4)/V82A -10,5(-10,28)/I84V -10,7 (-10,26) -10,4(-10,18)/-10,1(-9,92)/-10,8(-10,48)/-10,4(-10)/ -10,4(-10,18)/-10,4(-9,8)/-
10,4(-10,02)/-10,7(-10,46)
Lopinavir -10,3(-9,84) -9,9(-9,56)/V32I -9,4(-8,92)/I47V -9,5(-8,62)/L76V -9,7(-9,24)/V82A -9,7(-9,14) -9,9(-9,56) /-9,7(-9,18) /-9,6(-9,24)/-9,3(-8,86)/ -9(-8,32)/-9,6(-9)/-9,5(-9,2)/-9,6
(-9,42)
Nelfinavir -10,3(-9,46) -10(-9,44)/D30N -10,1(-9,8)/L90M -9,9(-9,46) -10,1(-9,62) /-10,4(-9,8)/-10,1(-9,74)/-10(-9,84)/ -10,1(-9,72)/-10,1(-9,74) /-10
(-9,78)/-10,1(-9,7)
Saquinavir -10,9(-10,46) -10,9(-10,6)/G48V -10,4(-10,2)/L90M -10,9 (-10,54) -9,9(-9,64)/-10,3(-9,62) /-10,4(-10,06)/-10,6(-10,44)/ -10,6(-10,42)/-10,6
(-10,42)/ -10,6(-10,5)/-10,5(-10,2)
Tipranavir -10,6(-10,1) -10,4(-9,8)/I47V -10,3(-10,04)/Q58E -10,2(-10,0)/T74P -10,4(-9,9)/V82L -10,2
(-9,6)/N83D -10,6(-10,12)/I84V
-9,9(-9,64) -10,2(-9,62) /-10,1(-9,92) /-10,3(-9,98)/-10,2(-9,88)/ -10,2(-9,72)/-10,3(-9,72)/-
10,3(-9,72)/-10,2(-9,78)
Ritonavir -8,0(-7,85) -7,82(-7,44)/I47V -7,8(-7,56)/I50V -7,4(-6,94)/V82L -7,87(-7,58)/I84V -7.9
(-7,72)/L90M
-7,26(-6,69) -8,3(-7,93)/-7,85(-7,54)/ -7,75(-7,52)/-7,9(-7,76)/ -8,3(-8,14)/-8,2(-8,09)/-8,4
(-8,8)/-7,79(-7,52)
The average value of the five conformations with less free energy of binding of the protease-PI complex is presented in parentheses. Values that do not correspond to decreasing order of free energy of binding are




















Figure 6 HIV-1 protease structures. Wild-type (WT), resistant and D29V mutant proteases coupled to darunavir (top) and tipranavir (bottom).
The numbers in the left upper corner are the PDB ID numbers used to model darunavir and tipranavir with the protease and to measure the dis-
tance (Å) between functional groups (purple).
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http://www.biomedcentral.com/1471-2105/15/72and TPV (Figure 6). For each natural polymorphism and
unusual mutation, Table 5 shows the degree of resistance
to PIs based on free energy of binding differences when
compared with reference PRs.
Of the emerging mutations, D29V appears to favour re-
sistance in silico in seven of nine PIs. Designing more ef-
fective DRV analogues requires an interaction between D29
and the bis-tetrahydrofuran ring, as this contributes to
complex stability [5,42]. All complexes that formed among
the PRs with natural polymorphisms, unusual mutations
and drug resistance mutations to TPV and LPV had similar
free energies of binding. TPV mainly forms hydrogen
bonds with residues D25, D29, D30, G48 and I50, while
LPV interacts with G27, D29 and D30. A study that eluci-
dated the mechanism by which PIs minimize the harmful
effects of resistance mutations, showed that TPV, ATV,
LPV, APV, IDV and DRV conserve their antiretroviral
activity in the presence of drug resistance mutations. This
phenomenon is due to the compensation of the loss of
enthalpy (ΔH) with an entropy gain (−TΔS), except in the
case of TPV [75]. Our results are consistent with another
report that showed isolated strains with a high level of
phenotypic resistance to LPV were susceptible to other
PIs [76]. This corresponds with PR resistance to TPV
and LPV that contain emerging mutations whose free ener-
gies of binding were greater than those obtained with wild-
type PR.
We found a high prevalence (89%) of L63PGHRS muta-
tions in HIV-1 variants isolated from Mexican individuals,
probably because of the prevalence of HIV-1 subtype B
[32,33]. In the present study, among the functional groups
found at position 63 (L63G, L63S, L63H and L63R), only
glycine had hydrophobic characteristics, while serine was
hydrophilic, and histidine and arginine were alkaline. These
four mutations conferred resistance to NFV, ATV, TPV and
LPV, most probably through an allosteric effect, given that
the substitutions were not located close to the residueswhere the PIs bind [10,74]. Few mutations at position 63
have been examined for their resistance effects to PIs. The
L63P mutation has a compensatory effect that increases
catalytic activity from 110% to 530%; when L63P is associ-
ated with M46I, it forms a combination that is resistant to
APV, IDV, LPV or NFV [9,77]. Residue 63 provides hydro-
phobic contacts between the slit of the loop formed by
amino acids 38–42 and a β-sheet (residues 59–63) [74]. Al-
though the study of mutations in this position has been
limited to L63P to assess the effect of mutations that pro-
vide non-hydrophobic characteristics, alternative mecha-
nisms could be shown by which HIV-1 PR compensates for
pharmacological stressors.
Clinical characteristics of patients with unusual mutations
at resistance sites and/or natural polymorphisms
Of the participating individuals, 48 of 151 (31.8%)
showed resistance to at least one PI. Of these, 34 (70.8%)
showed a high level of resistance, four (8.3%) showed
intermediate levels of resistance, and 10 (20.8%) showed
low level resistance.
Of the 151 sequences, 24 (15.9%) had one or more
unusual mutations at resistance sites and/or natural poly-
morphisms. They were isolated from 21 (87.5%) male and
three (12.5%) female patients; 70.8% of whom lived in the
central-east of Mexico, and 29.2% in the north-west. Of
these 24 patients, 23 (95.8%) received antiretroviral therapy,
and one (4.2%) was naïve to treatment. The nucleoside re-
verse transcriptase inhibitors (NRTIs) and non-nucleoside
reverse transcriptase inhibitors (NNRTIs) used, in order of
frequency, were AZT, 3TC, ddI, d4T, ddC, NVP, EFV and
ABC. The main PIs used were IDV, RTV and SQV. The
average viral load in this group of patients was 228,225
virus copies/mL and a mean CD4+ lymphocyte count of
223 cells/μL. According to the case definition of HIV infec-
tion and AIDS by the Centers for Disease Control and Pre-
vention (Atlanta, USA) [78], patients were classified as





aa/Chain-PIs Wild type Resistant Emergent Wild type Resistant Emergent
PR-IDV [2R5P] [1K6C] D29V PR-LPV [2Q5K] [1RV7] D29V
29/A-N2 6.1 6.1 5.4 25/A-O4 5.4 6.8 9.1
29/B-O4 3.9 4.2 4.8 25/B-O4 5.5 7.8 9.9
30/A-N2 6.5 6.6 6.3 29/A-O1 5.8 10.8 6
30/B-O4 6.3 6.4 7 29/B-O3 6 10.3 5.3
82/A-O2 10.1 10.7 11.2 30/A-O1 3.7 9.8 7.1
82/B-N1 6.1 6.2 7.5 30/B-O3 6.7 10.1 5.3
84/A-O2 8.3 8.2 9.3 84/A-O4 8.2 10.1 10.4
84/B-N1 7.9 7.9 8.4 84/B-O3 7.6 8.1 8.2
PR-SQV [3OXC] [3CYW] D29V PR-RTV [3NDX] [1RL8] D29V
29/A-OD1 4.1 5.3 3.5 29/A-O76 4 3.8 4.9
29/B-N3 6.1 6 7.5 29/B-N5 5.6 4 5.1
30/A-OD1 3.8 4.2 3.8 30/A-O76 6.1 6.1 6.9
30/B-N3 6.5 6.4 7.5 30/B-S3 4 5.5 8.8
48/A-ND2 3.4 5.6 7.9 82/A-N11 9.4 9.5 9.6
48/B-N3 4 6.3 6.3 82/B-O7 10.5 10.3 11.6
PR-APV [3NU3] [3NU4] D29V PR-DRV [IT3R] [2HS1] D29V
29/A-O6 4.5 4.2 4 29/A-O26 3.9 4.1 10.4
29/B-N3 4.3 4.6 7.6 29/B-N1 4.6 4.4 7.3
30/A-O6 4.5 3.8 3.8 30/A-O26 3.8 3.8 12.3
30/B-N3 3.3 3.7 10.7 30/B-N1 3.8 3.7 9.5
32/A-O6 6.6 6.6 6.9 32/A-O26 7.2 7.5 13.9
32/B-N3 6.3 6.3 15 32/B-N1 6.1 7.6 13.3
PR-TPV [2O4P] [1DS4] D29V PR-ATV [3EKY] [3OXX] D29V
29/A-N28 6.1 6.2 9.6 29/A-OAI 3.9 5.1 5.6
29/B-O1 9.1 9.4 8.4 29/B-OAJ 3.9 4 8.3
30/A-N28 6.2 6 8.7 30/A-OAI 6.1 6 8.7
30/B-O1 10 10.2 8.6 30/B-OAJ 6 6 8.5
82/A-O8 10.7 10 10.2 50/A-O1 5.7 5.6 4.8




















Table 5 Distances (Å) between the amino acid of the protease and the PI heteroatoms (Continued)
84/A-O8 8.3 8.1 8.5
84/B-O8 8.4 7.8 8.1
PR-NFV [3EKX] [2PYM] D29V
29/A-N12 5.9 6.3 5.8
29/B-O38 5 4.4 3.8
30/A-N12 6.4 6.7 6.3
30/B-O38 3.9 3.7 3.7
The classification of atoms corresponds to the PDB file visualized in PyMOL. Measurements correspond to the distance between the alpha carbon of the PR amino acids and the heteroatoms of the inhibitor, and are
expressed as number of amino acids/chain PR − PI heteroatom.
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AIDS (n = 12, 50%), and of unknown clinical category (n =
4, 16.5%).
Conclusions
The use of bioinformatics to identify potential mutations that
confer resistance to antiretroviral drugs allows researchers to
develop realistic three-dimensional models that illustrate the
atomic interactions between an enzyme and its substrate. In
silico, the structural correlation of natural polymorphisms
and unusual mutations of drug resistance codons, allows the
identification of HIV-1 variants resistant to PIs. The D29V
mutation increases the probability of resistance to PIs as it
generates unstable complexes at the HIV-1 protease active
site. The prevalence of this mutation in different populations
should be further studied, and parallel crystallographic stud-
ies are required to confirm our in silico findings.
Among mutant PRs-PIs complexes evaluated, TPV and
LPV had free energies of binding greater than those ob-
tained with wild-type PRs.
Furthermore, the presence of a high rate of L63P, I93L,
V77I and I62V polymorphisms among the Mexican popula-
tion is similar to that observed in patients that underwent
antiretroviral treatments in other American and western
European countries. These data reinforced the knowledge
regarding the molecular epidemiology of the HIV-1 subtype
B in Mexico through the presence of HIV polymorphisms.
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